DNase 1 activity in patients with systemic lupus erythematosus: Relationship with epidemiological, clinical, immunological and therapeutical features

Lupus

Volumn 18, Issue 5, 2009, Pages 418-423

  Martinez Valle, F ^a   Balada, E ^a   Ordi Ros, Josep ^a   Bujan Rivas, S ^a   Sellas Fernandez, A ^a   Vilardell Tarres, M ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Auto antibodies; Disease activity; DNase1 activity; Systemic lupus erythematosus

Indexed keywords

CARDIOLIPIN ANTIBODY; CHLOROQUINE; CORTICOSTEROID; DEOXYRIBONUCLEASE I; DNA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LA ANTIBODY; LUPUS ANTICOAGULANT; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SM ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MEGADOSE; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTINUCLEAR; CASE-CONTROL STUDIES; DEOXYRIBONUCLEASE I; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 63749091863     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308098189     Document Type: Article

References (53)

1. Sherer Y Gorstein A Fritzler MJ Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: More than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004; 34: 501-537.
2. Rahman A Kumar S Potter KN. Anti-DNA antibodies-structure and function. Lupus 2002; 11: 776-779.
3. Blatt NB Glick GD. Anti-DNA autoantibodies and systemic lupus erythematosus. Pharmacol Ther 1999; 83: 125-139.
4. Burlingame RW Cervera R. Anti-chromatin (anti-nucleosome) autoantibodies. Autoimmun Rev 2002; 1: 321-328.
5. White S Rosen A. Apoptosis in systemic lupus erythematosus. Curr Opin Rheumatol 2003; 15: 557-562.
6. Dieker JW van der Vlag J Berden JH. Triggers for anti-chromatin autoantibody production in SLE. Lupus 2002; 11: 856-864.
7. Nagata S. Mutations in the Fas antigen gene in lpr mice. Semin Immunol 1994; 6: 3-8.
8. Watanabe-Fukunaga R Brannan CI Copeland NG Jenkins NA Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314-317.
9. Roths JB Murphy ED Eicher EM. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J Exp Med 1984; 159: 1-20.
10. Herrmann M Winkler T Gaipl U Lorenz H Geiler T Kalden JR. Etiopathogenesis of systemic lupus erythematosus. Int Arch Allergy Immunol 2000; 123: 28-35.
11. Herrmann M Voll RE Zoller OM Hagenhofer M Ponner BB Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41: 1241-1250.
12. Kalden JR. Defective phagocytosis of apoptotic cells: Possible explanation for the induction of autoantibodies in SLE. Lupus 1997;6:326-327.
13. Tax WJ Kramers C van Bruggen MC Berden JH. Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus. Kidney Int 1995; 48: 666-673.
14. Walport MJ. Lupus, DNase and defective disposal of cellular debris. Nat Genet 2000; 25: 135-136.
15. Graham KL Utz PJ. Sources of autoantigens in systemic lupus erythematosus. Curr Opin Rheumatol 2005; 17: 513-517.
16. Berden JH. Lupus nephritis. Kidney Int 1997; 52: 538-558.
17. Banchereau J Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
18. Albert ML Sauter B Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86-89.
19. Savill J Dransfield I Gregory C Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002; 2: 965-975.
20. Henson PM Bratton DL Fadok VA. The phosphatidylserine receptor: A crucial molecular switch. Nat Rev Mol Cell Biol 2001; 2: 627-633.
21. Rosen A Casciola-Rosen L. Autoantigens as substrates for apoptotic proteases: Implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ 1999; 6: 6-12.
22. Cragg MS Howatt WJ Bloodworth L Anderson VA Morgan BP Glennie MJ. Complement mediated cell death is associated with DNA fragmentation. Cell Death Differ 2000; 7: 48-58.
23. Mannherz HG Peitsch MC Zanotti S Paddenberg R Polzar B. A new function for an old enzyme: The role of DNase I in apoptosis. Curr Top Microbiol Immunol 1995; 198: 161-174.
24. Napirei M Wulf S Mannherz HG. Chromatin breakdown during necrosis by serum Dnase1 and the plasminogen system. Arthritis Rheum 2004; 50: 1873-1883.
25. Laskowski M. Deoxyribonuclease I. 3rd ed. NY: New York Academic Press; 1971.
26. Lacks SA. Deoxyribonuclease I in mammalian tissues. Specificity of inhibition by actin. J Biol Chem 1981; 256: 2644-2648.
27. Chitrabamrung S Rubin RL Tan EM. Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus. Rheumatol Int 1981; 1: 55-60.
28. Napirei M Karsunky H Zevnik B Stephan H Mannherz HG Moroy T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 2000; 25: 177-181.
29. Macanovic M Lachmann PJ. Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay. Clin Exp Immunol 1997; 108: 220-226.
30. Boes M Schmidt T Linkemann K Beaudette BC Marshak-Rothstein A Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A 2000; 97: 1184-1189.
31. Ehrenstein MR Cook HT Neuberger MS. Deficiency in serum immunoglobulin (Ig)M predisposes to development of IgG autoantibodies. J Exp Med 2000; 191: 1253-1258.
32. Korb LC Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: Complement deficiency and systemic lupus erythematosus revisited. J Immunol 1997; 158: 4525-4528.
33. Gaipl US Kuenkele S Voll RE et al. Complement binding is an early feature of necrotic and a rather late event during apoptotic cell death. Cell Death Differ 2001; 8: 327-334.
34. Fishelson Z Attali G Mevorach D. Complement and apoptosis. Mol Immunol 2001; 38: 207-219.
35. Bickerstaff MC Botto M Hutchinson WL et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999; 5: 694-697.
36. Butler PJ Tennent GA Pepys MB Pentraxin-chromatin interactions: Serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin. J Exp Med 1990; 172: 13-18.
37. Teh LS Bedwell AE Isenberg DA et al. Antibodies to protein P in systemic lupus erythematosus. Ann Rheum Dis 1992; 51: 489-494.
38. Chitrabamrung S Bannett JS Rubin RL Tan EM. A radial diffusion assay for plasma and serum deoxyribonuclease I. Rheumatol Int 1981; 1: 49-53.
39. Licht R Dieker JW Jacobs CW Tax WJ Berden JH. Decreased phagocytosis of apoptotic cells in diseased SLE mice. J Autoimmun 2004; 22: 139-145.
40. Bell DA Morrison B VandenBygaart P. Immunogenic DNA-related factors. Nucleosomes spontaneously released from normal murine lymphoid cells stimulate proliferation and immunoglobulin synthesis of normal mouse lymphocytes. J Clin Invest 1990; 85: 1487-1496.
41. Gaipl US Sheriff A Franz S et al. Inefficient clearance of dying cells and autoreactivity. Curr Top Microbiol Immunol 2006; 305: 161-176.
42. Denny MF Chandaroy P Killen PD et al. Accelerated macrophage apoptosis induces autoantibody formation and organ damage in systemic lupus erythematosus. J Immunol 2006; 176: 2095-2104.
43. Gaipl US Beyer TD Heyder P et al. Cooperation between C1q and DNase I in the clearance of necrotic cell-derived chromatin. Arthritis Rheum 2004; 50: 640-649.
44. Pisetsky DS Jiang N. The generation of extracellular DNA in SLE: The role of death and sex. Scand J Immunol 2006; 64: 200-204.
45. Lockshin MD. Sex ratio and rheumatic disease: Excerpts from an Institute of Medicine report. Lupus 2002; 11: 662-666.
46. Lockshin MD. Invited review: Sex ratio and rheumatic disease. J Appl Physiol 2001; 91: 2366-2373.
47. Lazarides E Lindberg U. Actin is the naturally occurring inhibitor of deoxyribonuclease I. Proc Natl Acad Sci U S A 1974; 71: 4742-4746.
48. Macanovic M Sinicropi D Shak S Baughman S Thiru S Lachmann PJ. The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol 1996; 106: 243-252
49. Yasutomo K Horiuchi T Kagami S et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet 2001; 28: 313-314.
50. Tew MB Johnson RW Reveille JD Tan FK. A molecular analysis of the low serum deoxyribonuclease activity in lupus patients. Arthritis Rheum 2001; 44: 2446-2447.
51. Balada E Ordi-Ros J Hernanz S et al. DNASE I mutation and systemic lupus erythematosus in a Spanish population: Comment on the article by Tew, et al. Arthritis Rheum 2002; 46: 1974-1976 author reply 1976-1977.
52. Nadano D Yasuda T Kishi K. Measurement of deoxyribonuclease I activity in human tissues and body fluids by a single radial enzyme-diffusion method. Clin Chem 1993; 39: 448-452.
53. Sallai K Nagy E Derfalvy B Muzes G Gergely P. Antinucleosome antibodies and decreased deoxyribonuclease activity in sera of patients with systemic lupus erythematosus. Clin Diagn Lab Immunol 2005; 12: 56-59.